SBI Okasan Asset Management Co.Ltd. Makes New Investment in Vera Therapeutics, Inc. $VERA

SBI Okasan Asset Management Co.Ltd. bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,200 shares of the company’s stock, valued at approximately $1,578,000.

A number of other hedge funds have also made changes to their positions in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Vera Therapeutics by 7.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after acquiring an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after acquiring an additional 17,907 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after acquiring an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Vera Therapeutics by 550.5% during the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after acquiring an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after acquiring an additional 825 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the sale, the chief executive officer owned 216,744 shares in the company, valued at $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by corporate insiders.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $35.86 on Friday. Vera Therapeutics, Inc. has a one year low of $18.76 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The stock has a market cap of $2.57 billion, a PE ratio of -6.47 and a beta of 0.96. The stock has a 50 day moving average price of $38.58 and a 200 day moving average price of $41.16.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the business earned ($0.81) earnings per share. Equities research analysts expect that Vera Therapeutics, Inc. will post -6.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on VERA. Evercore set a $91.00 target price on Vera Therapeutics in a report on Friday, May 15th. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Wednesday, March 11th. HC Wainwright increased their price target on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $79.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.